Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
SEHK:2315 Voorraadrapport
Marktkapitalisatie: HK$2.3b
Biocytogen Pharmaceuticals (Beijing) Dividenden en inkoop
Dividend criteriumcontroles 0/6 Biocytogen Pharmaceuticals (Beijing) heeft geen dividenduitkeringen gedaan.
Belangrijke informatie
-0.004%
Terugkoop Rendement
Totaal aandeelhoudersrendement -0.004% Toekomstig dividendrendement 0% Dividendgroei n/a Volgende betaaldatum dividend n/a Ex-dividenddatum n/a Dividend per aandeel n/a Uitbetalingsratio n/a
Recente updates van dividend en inkoop
Toon alle updates
First half 2024 earnings released: CN¥0.13 loss per share (vs CN¥0.48 loss in 1H 2023) Sep 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Q2, 2024 Results on Aug 28, 2024 Aug 16
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment? May 08
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking Apr 03
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Annual General Meeting, May 28, 2024 Mar 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Annual General Meeting, May 28, 2024 Mar 28
Full year 2023 earnings released: CN¥0.96 loss per share (vs CN¥1.58 loss in FY 2022) Mar 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
New minor risk - Share price stability Feb 16
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company Dec 13
New minor risk - Share price stability Oct 06
Biocytogen Pharmaceuticals' RenMice Series-Fully Human Antibody and TCR Mouse Models-Showcase Biocytogen's Capabilities to Innovate the Discovery of Biologic Drugs Sep 15
Forecast to breakeven in 2025 Aug 31
First half 2023 earnings released: CN¥0.48 loss per share (vs CN¥0.73 loss in 1H 2022) Aug 30
New minor risk - Profitability Aug 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth Aug 18
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report First Half, 2023 Results on Aug 28, 2023 Aug 16
Forecast to breakeven in 2025 Mar 29
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Launches Rennano Mouse, Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery Dec 30
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces FDA Clearance of IND Application for Bispecific Antibody YH008 Dec 19
Less than half of directors are independent Nov 16
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Management Appointments Nov 08
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Resignation of Huang Xiaolu as Non-Executive Director and A Member of the Strategy Development Committee Oct 18
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Present at Biojapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress Sep 28
First half 2022 earnings released: EPS: CN¥0 (vs CN¥0 in 1H 2021) Sep 27
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has completed an IPO in the amount of HKD 548.74937 million. Sep 01
Less than half of directors are independent Sep 01
Stabiliteit en groei van betalingen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van 2315 in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van 2315 zijn gestegen.
Dividendrendement versus markt Biocytogen Pharmaceuticals (Beijing) Dividendrendement versus markt
Hoe verhoudt 2315 dividendrendement zich tot de markt? Segment Dividendrendement Bedrijf (2315) n/a Markt onderkant 25% (HK) 3.2% Markt Top 25% (HK) 8.0% Gemiddelde industrie (Biotechs) 1.1% Analist prognose (2315) (tot 3 jaar) 0%
Opmerkelijk dividend: Het dividendrendement van 2315 kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van 2315 kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio 2315 te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat 2315 geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
